Stocks · News reference
Dentsply Sirona Affirms FY2026 Adj EPS Guidance of $1.40-$1.50 vs $1.42 Est; Affirms FY2026 Sales Guidance of $3.500B-$3.600B vs $3.582B Est
Dentsply Sirona (NASDAQ:XRAY) affirms FY2026 Adj EPS guidance from $1.40-$1.50 to $1.40-$1.50 vs $1.42 analyst estimate. Affirms FY2026 sales outlook from $3.500 billion-$3.600 billion to $3.500 billion-$3.600 billion
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
BMO Capital Maintains Market Perform on Dentsply Sirona, Lowers Price Target to $10
BMO Capital analyst Vik Chopra maintains Dentsply Sirona (NASDAQ:XRAY) with a Market Perform and lowers the price target from $13 to $10.
XRAY's Q2 Earnings Beat Meets Steady Guidance and Margin Pressure
DENTSPLY SIRONA (XRAY) exceeded Q2 earnings and revenue estimates with adjusted EPS of 52 cents versus 36 cents consensus, though revenues fell 4.1% year-over-year. The company maintained full-year 2026 guidance of $3.5-3.6B in sales and $1.40-1.50 adjusted EPS. Wellspect Healthcare grew 7.1%, but three dental segments declined, with tariff pressures and lower volumes constraining operating margins. Free cash flow improved to $55M from $16M year-ago.
Barclays Maintains Underweight on Dentsply Sirona, Raises Price Target to $11
Barclays analyst Glen Santangelo maintains Dentsply Sirona (NASDAQ:XRAY) with a Underweight and raises the price target from $9 to $11.